Nanobody-Mediated Complement Activation to Kill HIV-Infected Cells

Investigators developed a novel therapeutic modality to direct complement activity to the surface of HIV-1-infected cells. The bispecific complement engager was comprised of a nanobody recruiting the complement-initiating protein C1q, and single-chain variable fragments of broadly neutralizing antibodies targeting the HIV-1 envelope protein.